Coronavirus vaccine reaches phase-2 trials in China

Small bottles labeled with "Vaccine"stickers stand near a medical syringe in front of displayed "Coronavirus COVID-19"words in this illustration taken April 10, 2020. Reuters. Sketched by the Pan Pacific Agency.
BEIJING, Jun 21, 2020, China Daily. An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday (Jun 20), according to the China Daily.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.